Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.309NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.309NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.1.309NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.309NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.1.309NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.1.309ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-17798.2Japan
B.1.105ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.105ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.105NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.105NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.105NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.105NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.105NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.105ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.1.8ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.1.8ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.1.8NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.1.8NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.1.8NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.1.8NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.1.8NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.1.8ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.177.11ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.177.11ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.177.11NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.177.11NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.177.11NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.177.11NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.177.11NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.177.11ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.258.7ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.258.7ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.258.7NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.258.7NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.258.7NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.258.7NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.258.7NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.258.7ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.1.307ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.1.307ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.1.307NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.307NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.1.307NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.307NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.1.307NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.1.307ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.1.171ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.1.171ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.1.171NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.171NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used